JEADV clinical practice最新文献

{"title":"Postoperative Pyoderma Gangrenosum After Breast Surgery: A Single-Centre Retrospective Study","authors":"Shirley P. Parraga,&nbsp;Jonathan D. Greenzaid,&nbsp;Matthew L. Hrin,&nbsp;Wasim A. Haidari,&nbsp;Kyle E. Robinson,&nbsp;Lindsay C. Strowd","doi":"10.1002/jvc2.624","DOIUrl":"https://doi.org/10.1002/jvc2.624","url":null,"abstract":"<p>Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis sometimes induced by trauma, including surgical procedures, through a process known as pathergy [<span>1</span>]. Breast surgery accounts for roughly 25% of postoperative PG (PSPG) cases [<span>1</span>]. Identifying factors associated with developing PSPG is critical for facilitating early recognition and timely intervention [<span>2, 3</span>]. In this study, we analysed the characteristics of patients who developed PSPG after breast surgery at our academic medical centre.</p><p>Institutional review board was obtained to review the medical records of patients evaluated at Atrium Health Wake Forest Baptist's dermatology clinic between 2010 and 2024 who were diagnosed with PG after breast surgery. A 2:1 randomized control cohort of patients who underwent similar procedures and did not develop PG was utilized for comparison. Parameters analysed included demographics, comorbid conditions, surgical procedures and characteristics, risk factors and postoperative complications. Statistical significance between the PSPG and control cohort was compared.</p><p>The PSPG (<i>n</i> = 11) and control cohort (<i>n</i> = 22) had similar demographic characteristics (Table 1). Associated medical conditions included previous episodes of PG (9% PSPG vs. 0% control, <i>p</i> = 0.33), prior malignancy (55% PSPG vs. 100% control, <i>p</i> = 0.002), and inflammatory arthritis (55% PSPG vs. 18% control, <i>p</i> = 0.05). Patients also had inflammatory skin disorders (36% PSPG vs. 5% control, <i>p</i> = 0.033). Only eczema and psoriasis were identified. No patients in either cohort had a history of leukaemia, lymphoma, or inflammatory bowel disease (Table 1). Patients more frequently developed PSPG following breast reconstruction (55% vs. 5%, <i>p</i> = 0.0025) and reduction (45% vs. 5%, <i>p</i> = 0.0096) compared to the control cohort (Table 1). No differences in suture type were observed between the cohorts (Table 1). The average time between surgery and the onset of PG symptoms was 3.91 months. Seven patients (64%) developed symptoms within 90 days of surgery.</p><p>Classic surgical risk factors were higher for PSPG patients compared to the control cohort (Table 1). Body mass index (BMI) was greater for PSPG patients (33.6 kg/m²) compared to the control group (26.6 kg/m², <i>p</i> = 0.0063). The PSPG cohort had more current or former smokers (63% vs. 41%, <i>p</i> = 0.28), diabetics (36% vs. 18%, <i>p</i> = 0.39) and a longer duration of surgical procedure (323 min vs. 226 min, <i>p</i> = 0.21), although these characteristics were not statistically significant. Mean estimated blood loss (EBL) was comparable for both groups.</p><p>Initial versus successful treatments for PSPG patients were also evaluated (Table 2). Most patients were initially treated with systemic antibiotics (73%) and debridement (45%, Table 2) for an average duration of 9.6 months before starting therapy with syste","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"584-586"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged Vancomycin-Induced Linear IgA Disease in a Patient With Renal Failure","authors":"Kaori Takezawa,&nbsp;Reiko Noborio,&nbsp;Yuki Nomura,&nbsp;Takahiro Kiyohara,&nbsp;Mako Mine,&nbsp;Takashi Hashimoto","doi":"10.1002/jvc2.622","DOIUrl":"https://doi.org/10.1002/jvc2.622","url":null,"abstract":"<p>A 64-year-old man with pneumococcal septic shock and subsequent renal failure underwent treatments with antibiotics including intravenous vancomycin (VCM). Blistering skin lesions appeared 10 days after the initiation of VCM. When the patient was transferred to us 5 months later, blisters with erythema were still observed on the abdomen and thighs. Histopathological examination revealed subepidermal blister with infiltration of eosinophils and neutrophils, and direct immunofluorescence revealed linear IgA deposition at the basement membrane zone. The diagnosis of linear IgA disease (LAD)was made, and drug-induced LAD by VCM was suspected, because of the episode of the blister development 10 days after the first VCM administration. Although the results of various sero-immunological tests were negative, IgA reactivity with type Ⅶ collagen was detected by VCM-treated ELISA, which further suggested the diagnosis of VCM-induced LAD. The possible mechanism for the prolonged disease course was speculated.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"535-539"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.622","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Where Is Waldo?","authors":"Lilia Maria Lima de Oliveira,&nbsp;Uzma Farooq,&nbsp;Samir Ahmad,&nbsp;Naiara Fraga Braghiroli","doi":"10.1002/jvc2.620","DOIUrl":"https://doi.org/10.1002/jvc2.620","url":null,"abstract":"<p>A 76-year-old man presented to the clinic for a total body examination. He had a personal history of five melanomas in situ, five basal cell carcinomas, and three squamous cell carcinomas. The dermatological examination revealed sun-damaged skin with three similar irregular brown macules on the left superior back, left medial trapezium, and mid-upper back (Figure 1). Dermoscopy of the three macules was comparable, revealing multicomponent features (Figure 1).</p><p>A biopsy was performed, and histology revealed one melanoma in situ and two solar lentigo (Figure 2). The melanoma was subsequently excised with 5 mm margins. Currently, the patient is being closely monitored.</p><p>In this case study, the three macules exhibited clinical and dermoscopic features that could be attributed to the diagnosis of melanoma. The presence of several nevi, extensively sun-damaged skin, and a significant history of skin cancer made the diagnosis even more challenging. Digital monitoring enables close observation and timely intervention, but in patients with suspected lesions of melanoma, early surgical excision is key. This case highlights the importance of a complete skin check and the challenge of diagnosing pigmented skin lesions in patients with severe sun damage.</p><p><b>Lilia Maria Lima de Oliveira:</b> conceptualization, drafting and reviewing the manuscript, and final approval of the submitted version. <b>Uzma Farooq:</b> conceptualization, drafting and reviewing the manuscript, and final approval of the submitted version. <b>Samir Ahmad:</b> conceptualization, drafting and reviewing the manuscript, and final approval of the submitted version. <b>Naiara Fraga Braghiroli:</b> conceptualization, drafting and reviewing the manuscript, and final approval of the submitted version.</p><p>All patients in this manuscript have given written informed consent for participation in the study and the use of their de-identified, anonymized, aggregated data and their case details (including photographs) for publication. Ethical approval is not applicable.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"593-594"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.620","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-12/23 and Interleukin-23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi-Institutional Registry","authors":"G. E. McKay,&nbsp;A. Coromilas,&nbsp;L. Liu,&nbsp;K. S. Shaw,&nbsp;M. Murphy,&nbsp;N. Punyamurthy,&nbsp;K. M. Santiago Soltero,&nbsp;W. Damsky,&nbsp;K. A. Wanat,&nbsp;A. P. Charrow,&nbsp;M. Rosenbach,&nbsp;A. Caplan,&nbsp;C. E. LaSenna,&nbsp;L. Arkin,&nbsp;B. E. Shields","doi":"10.1002/jvc2.615","DOIUrl":"https://doi.org/10.1002/jvc2.615","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cutaneous Crohn's disease (CCD) is a granulomatous condition of the skin discontiguous from the gastrointestinal tract. Cutaneous disease rarely correlates with intestinal disease and often requires separate treatment. While the use of interleukin-12/23 (IL-12/IL-23) and interleukin-23 (IL-23) inhibitors is FDA-approved for intestinal Crohn's disease (CD), there is limited data for CCD. We retrospectively reviewed the clinical features of 24 cases of CCD treated with risankizumab as monotherapy, ustekinumab as monotherapy, or ustekinumab in combination with vedolizumab from seven academic institutions across the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study was to evaluate the impact of IL-12/23 or IL-23 inhibitor therapy on CCD independent of intestinal disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients were identified by retrospective review of the electronic health record including histopathologic diagnosis consistent with CCD. At least one visit with a dermatologist between 2000 and 2020 was required. Chart review collected demographic, clinical and histologic data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 24 adult and paediatric patients with CCD treated with IL-12/IL-23 inhibitor therapy. Most patients were White (21/24, 88%), female (20/24, 83%), had intestinal CD (19/24, 79%), were diagnosed with intestinal CD before CCD diagnosis (18/24, 75%), and were on biologic therapy before CCD diagnosis (16/24, 67%). Most patients failed to respond to treatment with anti-tumour necrosis alpha (anti-TNF) therapy before IL-12/IL-23 inhibitor therapy (22/24, 92%). Of the 24 patients treated with ustekinumab, less than half (7/24, 29%) were simultaneously treated with vedolizumab. Four adult patients (4/24, 17%) were treated with risankizumab monotherapy. At the date of the last follow-up with a dermatologist, over a third (8/24, 33%) of patients' skin was reported as complete clearance by physician note.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We propose that IL-12/IL-23 and IL-23 inhibitor therapy be considered as therapy for the treatment of TNF-blockade refractory CCD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"458-462"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab","authors":"Lukas D. Uleer,&nbsp;Carmen Loquai,&nbsp;Iakov Shimanovich,&nbsp;Cyrus Khandanpour,&nbsp;Jasper N. Pruessmann,&nbsp;Patrick Terheyden,&nbsp;Christian D. Sadik","doi":"10.1002/jvc2.570","DOIUrl":"https://doi.org/10.1002/jvc2.570","url":null,"abstract":"<p>Mycosis fungoides (MF) is the most common cutaneous T cell lymphoma. Since 2018, mogamulizumab, an antibody directed to to the chemokine receptor CCR4, is licensed for the treatment of MF. Treatment with mogamulizumab is associated with the precipiation of different types of skin rashes summarized as mogamulizumab-associated rash. Here, we report the emergence of severe bullous pemphigoid (BP) in a patient suffering from severe MF and treated with mogamulizumab. BP is an autoimmune blistering skin disease causing severe pruritus and subepidermal blisters and, consequently, erosions. It is driven by autoantibodies against BP180, a protein of the dermal-epidermal adhesion complex. The parallel occurrence of MF and BP led to a bizarre clinical and histopathological presentation blending features of MF and BP. Among others, the patient developed multiple large erosions with a diameter of up to 15 cm, and histopathology featured subepidermal clefts with a mixed dermal infiltrate and atypical lymphocytes forming a superficial dermal lichenoid infiltrate and showing epidermotropism, including above the subepidermal clefts. Immunopathology revealing linear depositions of IgG and C3 at the dermal-epidermal junction and very high serum levels of anti-BP180-NC16A IgG were instrumental to diagnose BP and to distinguish it from mycosis fungoides bullosa, an extremely rare variant of MF. This case illustrates that immunopathology for BP should be conducted in patients with MF developing pruritus and blisters, although both can also be a symptom of MF. Our case alone does not allow determining whether the emergence of BP under mogamulizumab treatment was a mere coincidence or was in a causal relationship. The latter scenario would at BP to the possible clinical presentations of mogamulizumab-associated rashes.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"503-506"},"PeriodicalIF":0.0,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.570","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sun Protective Clothing: A Cross-Sectional Analysis of Online Availability","authors":"Nicola Kearney,&nbsp;Mary Laing","doi":"10.1002/jvc2.616","DOIUrl":"https://doi.org/10.1002/jvc2.616","url":null,"abstract":"&lt;p&gt;Skin cancer is the most common cancer in the UK and Ireland, with the number of non-melanoma and melanoma skin cancer diagnoses in the UK expected to rise by 39% [&lt;span&gt;1&lt;/span&gt;] and 9% [&lt;span&gt;2&lt;/span&gt;] by 2040, respectively. The World Health Organisation (WHO) advocates for the use of photoprotective clothing including wide-brimmed hats, tightly woven clothing, and wraparound style sunglasses that provide 100% ultraviolet-A (UV-A) and ultraviolet-B (UV-B) protection to combat the deleterious effects of UV radiation and increasing skin cancer rates [&lt;span&gt;3&lt;/span&gt;]. The photoprotective standard of clothing is often measured as the ultraviolet photoprotective factor (UPF). UPF measures skin erythema at various UV radiation doses, and is analogous to the SPF of sunscreen [&lt;span&gt;4&lt;/span&gt;]. UPF is defined as the ratio of the average effective UV irradiance calculated for unprotected skin, to the average effective UV irradiance calculated for skin protected by a given fabric [&lt;span&gt;5&lt;/span&gt;]. The European Committee for Standardisation (CEN) has developed a standard on requirements for test methods and labelling of sun-protective garments. UV protective clothing for which compliance with this standard is claimed must have a UPF of greater than 40 (UPF 40+) and must maintain an average UVA transmittance of less than 5% [&lt;span&gt;6&lt;/span&gt;]. We aimed to investigate the frequency of UPF-rated photoprotective clothing sold online by the United Kingdom's largest retailers.&lt;/p&gt;&lt;p&gt;The UK's top 30 retailers based on annual revenue generated were identified for the year 2023–2024 [&lt;span&gt;7&lt;/span&gt;]. Each online retailer's website was searched for “UPF clothing” and “UPF” between September and December 2024 (Table 1). Seven online retailers were excluded as they did not sell clothing; the remaining 23 retailers were included for analysis in this study. Of the 23 remaining stores, 35% (8/23) sold UPF-rated clothing online. Three retailers sold UV protective clothing for men, women, and children, while this photoprotective clothing was less widely available on the remaining 5 retailer's online catalogues. Of the stores that did have UPF-rated clothing, 50% (4/8) had fewer than 15 UPF-graded items for sale; 25% (2/8) had over 200 UPF-graded items on their website. All UPF-rated clothing identified from these retailers websites were rated UPF 40+ or above, thereby complying with the CEN's guidance on UV protective clothing. The stores that had a selection of UPF-rated clothing on their website included Amazon, H&amp;M, John Lewis, JD Sports, NEXT, House of Fraser, Screwfix and Very. The vast majority of UPF rated clothing identified were activewear and children's swimwear; there was a scarcity of “every day” casual clothing with a UPF rating.&lt;/p&gt;&lt;p&gt;Our online search of UPF-rated garments revealed that this photoprotective clothing is not readily available, with only 35% of the UK's largest online retailers stocking UPF-rated clothing. The poor availability of UPF-grade","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"577-579"},"PeriodicalIF":0.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.616","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory Pyostomatitis Vegetans With Multiple Aseptic Cutaneous Abscesses Successfully Treated With Filgotinib in Ulcerative Colitis","authors":"C. Dandoy,&nbsp;D. Franchimont,&nbsp;C. Delvaux,&nbsp;A. Buggenhout,&nbsp;D. Bernardi,&nbsp;V. Del Marmol,&nbsp;J. M. L. White","doi":"10.1002/jvc2.597","DOIUrl":"https://doi.org/10.1002/jvc2.597","url":null,"abstract":"<p>We report on a 31-year-old male patient diagnosed with active moderate-to-severe ulcerative colitis and a history of splenectomy. He was hospitalized due to confluent pustular oral lesions and multiple skin abscesses. After ruling out an infection, we diagnosed pyostomatitis vegetans associated with aseptic abscess syndrome. After multiple unsuccessful treatments (corticosteroids, infliximab, ciclosporin, ustekinumab and colectomy), filgotinib, a JAK 1 inhibitor, was then initiated, resulting in the complete resolution of skin lesions.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"507-509"},"PeriodicalIF":0.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.597","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life retrospective multicentre study to describe the use of dupilumab in paediatric patients with atopic dermatitis in Spain: Patient profile, effectiveness and safety","authors":"Eulalia Baselga Torres,&nbsp;Marta Ivars,&nbsp;Carolina Prat,&nbsp;Asunción Vicente,&nbsp;Marta Feito Rodríguez,&nbsp;Rocío Maseda Pedrero,&nbsp;Ana Martín Santiago,&nbsp;Aniza Giacaman,&nbsp;Antonio Torrelo Fernández,&nbsp;Lucero Noguera-Morel,&nbsp;Isabel Betlloch Mas,&nbsp;Laura de Berbegal Gracia,&nbsp;Montserrat Évole Buselli,&nbsp;Mónica Pozuelo Ruiz,&nbsp;José Bernabéu Wittel,&nbsp;María T. Monserrat García,&nbsp;Minia Campos Domínguez,&nbsp;Cristina Galache Osuna,&nbsp;Jorge Santos-Juanes Jiménez,&nbsp;Altea Esteve Martínez,&nbsp;Violeta Zaragoza Ninet,&nbsp;Miquel Casals Andreu,&nbsp;Sara I. Palencia Pérez,&nbsp;José Suárez Hernández,&nbsp;Sara Dorta Alom,&nbsp;Laura Feliciano Divasson,&nbsp;Ana Batalla Cebey,&nbsp;Manuel Galán Gutiérrez,&nbsp;Raúl de Lucas Laguna","doi":"10.1002/jvc2.565","DOIUrl":"https://doi.org/10.1002/jvc2.565","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dupilumab, inhibiting interleukin 4 and 13, is the first monoclonal antibody licensed for atopic dermatitis (AD) since 6 months of age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The study describes the patients' profile, the effectiveness and safety in real life of dupilumab in adolescents with moderate-severe AD and children with severe AD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>National, multicentre, observational, and retrospective study, based on medical records' data extracted in September 2023. Patients included were adolescents (12–17 years) with moderate-severe AD (Eczema Area and Severity Index [EASI] ≥ 16) and children (6–11 years) with severe AD (EASI ≥ 21) at the start of dupilumab therapy and treated with dupilumab for at least 3 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 211 analysed patients, at dupilumab treatment onset, 69.6% registered an Investigator's Global Assessment (IGA) = 4, a median Dermatology Life Quality Index (DLQI) = 17, and a median Peak Pruritus Numerical Rating Scale (PP-NRS) = 8. Atopic comorbidities were present in 69.7% of the patients. Overall, 97.1% of the patients had received systemic treatments before dupilumab, being oral corticosteroids (75.5%) the most frequent. At 16 and 52 weeks, the mean EASI percentage reductions from baseline were −77.5% and −84.7%, respectively, and 71.8% and 82.4% of the patients achieved EASI ≤ 7. A total of 70.5% and 36.5% (16 weeks), and 78% and 48.4% (52 weeks) of the patients had EASI-75 and EASI-90, respectively. At week 52, 70% and 87% of the patients achieved a reduction of ≥4 PP-NRS points and of ≥6 DLQI points, respectively. No serious dupilumab-related adverse events were reported; 6.2% presented treatment-related conjunctivitis and 1.4% reported eosinophilia, but without treatment discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The study population had a pronounced disease burden as defined by signs, symptoms, quality of life, atopic comorbidities, and the systemic treatments' use prior dupilumab. In a short time (16 weeks), dupilumab treatment demonstrated clinically relevant improvement with an acceptable safety profile, continued over 52 weeks.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"416-424"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.565","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Health and Well-Being Support for Individuals Living With Skin Conditions: A Global Landscape Analysis of Patient Needs and Current Resources","authors":"Tammi Shipowick,&nbsp;Jennifer Austin,&nbsp;Nicole Sudiacal,&nbsp;Stephanie Miller,&nbsp;Jennifer A. Pereira,&nbsp;Christine Bundy","doi":"10.1002/jvc2.606","DOIUrl":"https://doi.org/10.1002/jvc2.606","url":null,"abstract":"<p>The impact of skin diseases can be devastating, encompassing physical symptoms such as bumps, rashes, hyper- or loss of pigmentation, redness, itch, pain and scarring. The consequences on mental health and well-being are often more detrimental, impacting the ability to conduct routine daily activities and engage socially. Given the prevalence of dermatological conditions, it is critical that resources are available to address these needs. We conducted a review of dermatology patient advocacy groups and health organizations’ websites to determine what types of resources to support mental health and well-being currently exist globally for individuals with skin conditions and identified 26 websites featuring resources such as sections dedicated to providing mental health information, programs on mental health topics and coping strategies, peer support forums, and counselling. Clinical trials and observational studies have demonstrated that many of these tools improve key mental health and well-being-related symptoms. In order for new and existing resources to be effective on a global scale, they should be delivered through methods that are sensitive to a spectrum of mental health-related stigma, and cultural beliefs. In parts of the world where individuals value privacy above openly speaking about one's feelings, or where smartphone adoption is ubiquitous (i.e., Europe, South-East Asia), digital health resources might hold the most potential for uptake. In regions such as Africa, and remote and rural Western Pacific, task-shifting, a process whereby laypeople are trained by health professionals to deliver community-based interventions, may be a promising format given mental health professional shortages. To provide optimal support for the mental health and well-being of those around the world with skin conditions, future efforts should focus on evaluation of the patient benefits offered by existing resources, and their adaptation and expansion to befit other world regions, and align with varied cultural needs and beliefs.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"595-611"},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.606","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic Contact Dermatitis to a Temporary Henna Tattoo","authors":"Hashim S. Kaderbhai,&nbsp;Marlous L. Grijsen","doi":"10.1002/jvc2.612","DOIUrl":"https://doi.org/10.1002/jvc2.612","url":null,"abstract":"<p>A 23-year-old healthy Somali woman presented at our hospital in Nairobi, Kenya, with firm blisters on both forearms that appeared 48 h after applying a henna tattoo for a traditional wedding (Figure 1 A,B). She had experienced similar, albeit milder, symptoms following a henna tattoo application 2 years prior, which had resolved spontaneously. The distinct history and clinical presentation led to the diagnosis of allergic contact dermatitis to para-phenylenediamine (PPD). Treatment involved topical corticosteroids. Epicutaneous patch testing was not available nor affordable in our setting.</p><p>PPD is a potent sensitizer commonly found in hair and textile dyes and is increasingly used in temporary henna tattoos to extend longevity, expedite the drying process and intensify the colouring [<span>1</span>]. The patient's re-exposure to PPD triggered a delayed-type hypersensitivity reaction. Henna is a natural dye derived from the <i>Lawsonia inermis</i> plant and is a weak sensitizer. It has been used for centuries in Africa, Asia and the Middle East for medicinal and decorative purposes and typically lasts 5−7 days [<span>2</span>]. The increasing popularity of long-lasting temporary henna tattoos containing PPD has been associated with an increase in reported allergic skin reactions [<span>1</span>]. Reports indicate that the concentration of PPD in henna tattoos is alarmingly high, often exceeding regulated levels [<span>3</span>], further elevating the risk of allergic reactions.</p><p>H.S.K. drafted the manuscript, and M.L.G. critically revised it. Both authors reviewed and approved the final manuscript and gave consent for publication.</p><p>The authors have nothing to report. The patient in this manuscript has provided written informed consent for the use of her deidentified anonymized data and her case details (including photographs) for publication. Ethical Approval: not applicable.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"333-334"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.612","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}